Insider Transactions in Q1 2021 at Precision Biosciences Inc (DTIL)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 18
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,665
-0.24%
|
$106,315
$11.08 P/Share
|
|
Mar 18
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.54%
|
$0
$0.04 P/Share
|
|
Mar 17
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,665
-0.24%
|
$96,650
$10.92 P/Share
|
|
Mar 17
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.54%
|
$0
$0.04 P/Share
|
|
Mar 16
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,661
-0.24%
|
$106,271
$11.97 P/Share
|
|
Mar 16
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.54%
|
$0
$0.04 P/Share
|
|
Mar 12
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,712
-0.5%
|
$106,832
$11.36 P/Share
|
|
Mar 12
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.1%
|
$0
$0.04 P/Share
|
|
Mar 11
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,711
-0.5%
|
$106,821
$11.38 P/Share
|
|
Mar 11
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.1%
|
$0
$0.04 P/Share
|
|
Mar 10
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,710
-0.51%
|
$106,810
$11.79 P/Share
|
|
Mar 10
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.11%
|
$0
$0.04 P/Share
|
|
Feb 26
2021
|
Shane Barton VP & Corporate Controller |
BUY
Grant, award, or other acquisition
|
Direct |
1,294
+50.0%
|
$5,176
$4.61 P/Share
|
|
Feb 26
2021
|
Dario Scimeca General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
2,748
+25.62%
|
$10,992
$4.61 P/Share
|
|
Feb 22
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,660
-0.24%
|
$115,920
$12.04 P/Share
|
|
Feb 22
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.54%
|
$0
$0.04 P/Share
|
|
Feb 19
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,663
-0.25%
|
$106,293
$11.55 P/Share
|
|
Feb 19
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.54%
|
$0
$0.04 P/Share
|
|
Feb 18
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,705
-0.51%
|
$116,460
$12.23 P/Share
|
|
Feb 18
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.12%
|
$0
$0.04 P/Share
|
|
Feb 18
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,871
-0.17%
|
$82,452
$12.2 P/Share
|
|
Feb 18
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.54%
|
$0
$0.04 P/Share
|
|
Feb 17
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,705
-0.51%
|
$116,460
$12.28 P/Share
|
|
Feb 17
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.13%
|
$0
$0.04 P/Share
|
|
Feb 16
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,697
-0.52%
|
$126,061
$13.3 P/Share
|
|
Feb 16
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.13%
|
$0
$0.04 P/Share
|
|
Jan 29
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,444
-0.16%
|
$77,328
$12.25 P/Share
|
|
Jan 29
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,515
+0.55%
|
$0
$0.04 P/Share
|
|
Jan 28
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,444
-0.17%
|
$70,884
$11.97 P/Share
|
|
Jan 28
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.55%
|
$0
$0.04 P/Share
|
|
Jan 27
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,048
-0.18%
|
$77,528
$11.68 P/Share
|
|
Jan 27
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.55%
|
$0
$0.04 P/Share
|
|
Jan 26
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,697
-0.52%
|
$126,061
$13.37 P/Share
|
|
Jan 26
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,515
+1.14%
|
$0
$0.04 P/Share
|
|
Jan 25
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,695
-0.52%
|
$126,035
$13.74 P/Share
|
|
Jan 25
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.15%
|
$0
$0.04 P/Share
|
|
Jan 22
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
10,218
-0.56%
|
$132,834
$13.53 P/Share
|
|
Jan 22
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.16%
|
$0
$0.04 P/Share
|
|
Jan 21
2021
|
David S. Thomson Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-8.39%
|
$160,000
$16.49 P/Share
|